CHAPTERS
From podcast to Capitol Hill: how Buhler ended up testifying before the Senate
Joe asks Brigham what it’s like to testify before the Senate, and Brigham explains how quickly the opportunity came together. He credits relationships with Calley and Casey Means, and describes the goal of forming a bipartisan group to address chronic disease.
Inside the hearing: crowd turnout, Senate coaching, and pushing back on “Americans just want a pill”
Brigham describes the behind-the-scenes debrief, the unexpected public turnout, and the emotional reactions from attendees. He recounts senators advising the panel to be less confrontational, and his pushback against claims that people only want an easy pharmaceutical fix.
Regulatory capture and pharma influence: FDA funding, advertising, and the opioid disaster
The conversation shifts to structural incentives: FDA funding ties to industry and massive direct-to-consumer drug advertising. They connect these pressures to regulatory failures, including the opioid crisis.
Food system as upstream driver: 10,000 chemicals, Europe comparisons, and “Food Babe” examples
Brigham and Joe argue the chronic disease crisis begins with how food is grown, processed, and regulated. They contrast U.S. ingredient allowances with Europe and discuss examples where companies sell cleaner versions abroad.
The “woo-woo” backlash: hit pieces, fear, and why the panel says it’s about humanity
They address media attacks labeling the hearing “woo-woo” and accusing participants of profiteering. Brigham argues the panel was qualified and motivated by public health, while Joe criticizes narrative manipulation.
Compounding pharmacies and selective scrutiny: how narratives get built (and who benefits)
Brigham explains how compounding pharmacies are portrayed as unsafe while large manufacturers avoid comparable scrutiny due to overseas production and inspection barriers. He describes an article that effectively promotes a pharma product while attacking his business.
Follow-the-ownership money trail: Vanguard/BlackRock, PR firms, Monsanto, and PBMs
They broaden the critique to corporate ownership and influence across media and healthcare middlemen. Brigham revisits pharmacy benefit managers (PBMs), rebate structures, and alleged opacity that inflates costs and rewards chronic disease management over prevention.
GLP-1s, telemedicine testosterone, and the prevention-vs-profit tension
Joe and Brigham debate GLP-1 weight-loss drugs: useful for morbid obesity but risky when normalized for children or casual weight loss. They also discuss DEA scrutiny of telemedicine testosterone prescribing and how insurance rules create delays and gatekeeping.
Buhler’s personal health turnaround: diet change, protein focus, and hormone optimization
Joe asks about Brigham’s past health issues and what changed. Brigham details a shift from a typical busy “grab-and-go” diet to structured nutrition, then discovering extremely low testosterone and addressing it under medical supervision.
Insurance incentives and the opioid lesson: cheaper pills beat safer alternatives
Brigham argues the insurance/PBM ecosystem blocks prevention and often rejects non-addictive alternatives because of cost and rebate incentives. He uses opioid-era examples (topical pain creams and reduced toxicology screening coverage) to illustrate unintended consequences.
Pesticides, government PR, microplastics, and environmental exposure as health risks
Joe reads an excerpt alleging USDA-funded efforts to discredit pesticide critics and manage narratives. They discuss glyphosate exposure, microplastics, and broader environmental health concerns that intersect with chronic disease.
Building “preventive healthcare at scale”: AI-guided labs, wearables, vertical integration, and gamification
Brigham outlines a vision for using AI to interpret biomarkers, integrate wearables, and personalize prevention—while keeping clinicians in the loop. They argue this could expand access to comprehensive care and shift incentives away from late-stage intervention.
Late-show tangent into politics and society: polarization, immigration, disasters, and AI job displacement
The conversation sprawls into wider societal themes: how polarization blocks shared goals like health reform, plus immigration screening debates and disaster/insurance failures. They close with reflections on AI-driven job displacement, the need for purpose, and channeling “addiction energy” into health and discipline.
